NCT05390073

Brief Summary

Growth is extremely affected in epidermolysis bullosa patients

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2022

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 20, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 25, 2022

Completed
Same day until next milestone

Study Start

First participant enrolled

May 25, 2022

Completed
16 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 10, 2022

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2022

Completed
Last Updated

May 25, 2022

Status Verified

May 1, 2022

Enrollment Period

16 days

First QC Date

May 20, 2022

Last Update Submit

May 24, 2022

Conditions

Epidermolysis Bullosa Dystrophica

Outcome Measures

Primary Outcomes (1)

  • level of growth hormone and insulin like growth factor 1

    laboratory test

    2 weeks

Interventions

growth hormone level and insulin like growth factor 1DIAGNOSTIC_TEST

laboratory test

Eligibility Criteria

Age1 Month - 12 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

Children with EB dystrophica

You may qualify if:

  • \- Children with EB dystrophica

You may not qualify if:

  • Adults with the same disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • El Darouti M, Zaki IS, Mousa N, El Sayed H. Assessment of Growth Hormone and Insulin-Like Growth Factor 1 in Children With Epidermolysis Bullosa Dystrophica. Pediatr Dermatol. 2025 Nov 24. doi: 10.1111/pde.70113. Online ahead of print.

    PMID: 41287410DERIVED

MeSH Terms

Conditions

Epidermolysis Bullosa Dystrophica

Condition Hierarchy (Ancestors)

Epidermolysis BullosaSkin AbnormalitiesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesSkin Diseases, GeneticGenetic Diseases, InbornCollagen DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesSkin DiseasesSkin Diseases, Vesiculobullous

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

May 20, 2022

First Posted

May 25, 2022

Study Start

May 25, 2022

Primary Completion

June 10, 2022

Study Completion

June 15, 2022

Last Updated

May 25, 2022

Record last verified: 2022-05